title: Survival rates of sinonasal squamous cell carcinoma with the new AJCC staging system.
abstract: OBJECTIVE
  To investigate the validity of the sixth edition of the American Joint Committee on Cancer (AJCC) staging system for sinonasal squamous cell carcinoma.
  
  
  METHODS
  A 15-year retrospective case series review.
  
  
  METHODS
  Multicenter study from tertiary care facilities.
  
  
  METHODS
  Data from 113 patients diagnosed as having and treated for sinonasal squamous cell carcinoma from September 1988 through August 2003 were retrieved. Ninety patients followed up for at least 12 months were included in the study.
  
  
  METHODS
  The TNM staging system and survival rates were analyzed using the Kaplan-Meier method to determine the mean, disease-free, and 5-year survival statistics. The effect of tumor stage on overall survival was assessed with stages defined by the fifth and sixth editions of the AJCC staging systems.
  
  
  RESULTS
  The overall 5-year survival rate was 59.5%. According to the sixth edition, the survival rates of patients with stages III, IVA, and IVB tumors showed a significant difference (P = .002). In 32 cases, the stages were changed in accordance with the criteria in the sixth edition. The group in which the stage changed from III (fifth edition) to IVA (sixth edition) showed a worse survival rate than the group in which the stage did not change, although the difference was statistically insignificant. The 5-year disease-free survival rates of the group in which the stage did not change and of the group in which the stage changed from III (fifth edition) to IVA (sixth edition) were 64% and 34%, respectively (P = .08). Local recurrence was more frequently observed in the group in which the stage changed from III (fifth edition) to IVA (sixth edition).
  
  
  CONCLUSIONS
  The new AJCC staging system seems to be more accurate in predicting the survival rates for patients with advanced but surgically resectable sinonasal squamous cell carcinoma (stage IVA).
authors.affiliation: Department of Otorhinolaryngology-Head and Neck Surgery, Seoul National University College of Medicine, Seoul, Korea.
authors.forename: Chul Hee
authors.initials: CH
authors.lastname: Lee
authors.forename: Dong Gu
authors.initials: DG
authors.lastname: Hur
authors.forename: Hwan-Jung
authors.initials: HJ
authors.lastname: Roh
authors.forename: Ki-Sang
authors.initials: KS
authors.lastname: Rha
authors.forename: Hong-Ryul
authors.initials: HR
authors.lastname: Jin
authors.forename: Chae-Seo
authors.initials: CS
authors.lastname: Rhee
authors.forename: Yang-Gi
authors.initials: YG
authors.lastname: Min
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002294:Carcinoma, Squamous Cell / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009669:Nose Neoplasms / Q000401:mortality / Q000473:pathology* / Q000628:therapy; D012014:Reference Books, Medical; D015203:Reproducibility of Results; D012189:Retrospective Studies; D015996:Survival Rate